Shares of Indivior PLC (NASDAQ: INDV), a global pharmaceutical company specializing in substance use disorders, plummeted over 23% in the pre-market session on Thursday.
The sharp decline came after the company issued its guidance for fiscal year 2025, which was weaker than expected. According to the guidance, Indivior anticipates net revenue of $955 million to $1.025 billion for FY 2025, representing a 17% decrease at the midpoint compared to FY 2024.
Specifically, the company expects its SUBLOCADE net revenue to be in the range of $725 million to $765 million, which is relatively flat compared to FY 2024. However, the guidance suggests an accelerated decline in net revenue from SUBOXONE Film due to increased generic competition and the potential impact from a fifth buprenorphine/naloxone sublingual film generic entering the U.S. market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。